A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3361237 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs LY-3361237 (Primary) ; LY-3361237 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Sep 2019 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2018 Planned End Date changed from 7 Sep 2019 to 29 Aug 2019.